Historical Information

BASKING RIDGE, N.J. (November 1, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that Caladrius’ leadership

BASKING RIDGE, N.J. (October 2, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces the award of a $1,941,000 Small

BASKING RIDGE, N.J. (September 28, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that David J.

BASKING RIDGE, N.J. (September 7, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that the Company’s leadership

Milestone Achievement Triggered $2.4 Million Payments to Caladrius BASKING RIDGE, N.J. (September 5, 2017)  – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select

Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., (August 10, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS)  (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology

BASKING RIDGE, N.J., (August 3, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release

BASKING RIDGE, N.J. (July 19, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that 50% of subjects have been treated

BASKING RIDGE, N.J., (June 26, 2017) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cellular therapeutics development company with a pipeline focused on autoimmune disease and select cardiovascular indications, announces today that the Company has joined the Russell

Breakthrough platform technology enables researchers to more effectively develop new cell-based therapies for the treatment of cancers and other illnesses San Diego, CA and Basking Ridge, NJ (June 14, 2017)  –  Invetech , a global leader in instrument development, custom automation and contract